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Abstract
Background: Proactive palliative care is not yet common practice for patients with COPD. Important barriers are
the identification of patients with a poor prognosis and the organization of proactive palliative care dedicated to
the COPD patient. Recently a set of indicators has been developed to identify those patients with COPD
hospitalized for an acute exacerbation who are at risk for post-discharge mortality. Only after identification of these
patients with poor prognosis a multi disciplinary approach to proactive palliative care with support of a specialized
palliative care team can be initiated.
Methods/Design: The PROLONG study is a prospective cluster controlled trial in which 6 hospitals will participate.
Three hospitals are selected for the intervention condition based on the presence of a specialized palliative care
team. The study population consists of patients with COPD and their main informal caregivers. Patients will be
included during hospitalization for an acute exacerbation. All patients in the study receive standard care (usual
care). Besides, patients in the intervention condition who meet two or more criteria of the set of indicators for
proactive palliative care will have additionally regular consultations with a specialized palliative care team. The
objectives of the PROLONG study are: 1) to assess the discriminating power of the proposed set of indicators
(indicator study) and 2) to assess the effects of proactive palliative care for qualifying patients with COPD on the
wellbeing of these patients and their informal caregivers (intervention study). The primary outcome measure of the
indicator study is time to death for any cause. The primary outcome measure of the intervention study is the
change in quality of life measured by the St George Respiratory Questionnaire (SGRQ) three months after inclusion.
Discussion: The PROLONG study may lead to better understanding of the conditions to start and the effectiveness
of proactive palliative care for patients with COPD. Innovative aspects of the PROLONG study are the use of a set of
indicators for proactive palliative care, the active involvement of a specialized palliative care team and the use of a
patient-tailored proactive palliative care plan.
Trial registration: Netherlands Trial Register (NTR): NTR4037
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Background
In 2002 the World Health Organization (WHO) intro-
duced a new definition of palliative care. They empha-
sized in this definition the importance of early
identification and impeccable assessment and treatment
of pain and other problems, physical, psychosocial and
spiritual in order to prevent and relief suffering [1]. This
means that palliative care is not limited to the terminal
phase and can be delivered beside curative care to pa-
tients with a life-threatening illness. It implicates that
palliative care is not only restricted to reactive symptom
relief. By anticipating on expected disease scenario’s and
the specific needs and wishes of a patient, problems can
be prevented and hence quality of life improves. The
clinical use of this proactive palliative care is growing in
care for patients with cancer. Still a proactive approach
is not very common for patients with Chronic Obstruct-
ive Pulmonary Disease (COPD), even though the symp-
toms that occur in the end stage of COPD are as severe
or even worse than in the final stage of lung cancer
[2,3]. Both groups of patients prefer a treatment with the
emphasis on comfort instead of life prolongation, but to
patients with COPD this is offered less frequently [4].
For instance patients with COPD receive less opioids
and benzodiazepines than patients with lung cancer for
their dyspnea complaints [5], and they die more often at
an Intensive Care Unit (ICU) [6].
Several barriers are described with respect to offering
proactive palliative care to patients with COPD [7]. A
first important barrier is the identification of patients
with COPD who can benefit from proactive palliative
care, as it is difficult to predict the remaining length of
survival of these patients [8]. For that reason, recogniz-
ing the appropriate time to start proactive palliative care
may not be obvious for clinicians. A second important
barrier is the organization of proactive palliative care for
COPD patients. The majority of hospitals in Europe
have no formalized approach regarding palliative care
issues for patients with COPD: these patients have less
universal access to specialist palliative care services than
those with malignant lung diseases [9-11].
In general, an important problem in the transition or
referral to palliative care services is that the term “pallia-
tive care” is often associated with terminal or end stage
care only. This can be an impediment to early imple-
mentation of proactive palliative care as proposed by the
WHO. Especially for patients with COPD who do not
perceive COPD as an illness that disrupts life [12].
Hence the term ‘supportive care’ may be a term more
conducive to referral and may facilitate integration be-
tween curative care and palliative care for patients with
COPD [13-15]. Therefore, in this study we will speak of
supportive care in contact with participating patients
with COPD.
Identification of patients with COPD for proactive
palliative care
COPD illustrates the ‘organ failure’ end-of-life trajectory
in which a gradual decline is punctuated by acute severe
exacerbations, any one of which may be fatal [16,17].
The patient may survive the majority of these exacerba-
tions as long as he shows resilience and rebounds to (at
least part of ) his former condition. As it is unclear which
exacerbation will be fatal, death may seem to occur
suddenly [18] (Figure 1).
This uncertain prognosis makes it difficult for clini-
cians to initiate discussions about palliative care and
end–of–life care planning [19,20]. In stable COPD,
population models of 6 month survival do exist but they
are of limited value to predict death for individual pa-
tients [21]. It is therefore proposed to address proactive
palliative care at certain milestones in the course of the
disease [22], such as the occurrence of an acute exacer-
bation COPD (AECOPD) [20]. An AECOPD is defined
as ‘an acute worsening of the patient’s condition from
the stable state, which is sustained and may warrant the
patient to seek additional treatment’ [23]. Exacerbations
cluster in time with a high risk of recurrence within
8 weeks of recovery [24], and show an increasing fre-
quency as the disease progresses [25]. Recovery after an
AECOPD is often to a suboptimal condition as before
the exacerbation and after each exacerbation more care
may be required to support the patient and the family.
Therefore each admission to the hospital for an
AECOPD creates an opportunity to identify patients at
high risk of subsequent readmission or post-discharge
mortality and hence who can benefit from a proactive
palliative care approach. Several studies focused on the
identification of predictive factors associated with hos-
pital readmission or mortality for patients with an
AECOPD. The findings of these studies are summarized
in a recent review [26]. One of the conclusions is that
in-hospital mortality is related to the patient’s acute
physiological state and to the development of acute
comorbidity while post-discharge mortality particularly
Figure 1 COPD disease trajectory.
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reflects the severity of the underlying COPD, as well as
concomitant specific comorbidities. Important factors
influencing the frequency of readmission include func-
tional limitation and poor health-related quality of life.
A profile emerges of the types of patients hospitalized
for an AECOPD at high risk of subsequent readmission
or post-discharge mortality [19].
In accordance with these findings and based on exist-
ing literature [19,26-29] we developed a set of indicators
for lung specialists to improve the identification of pa-
tients hospitalized for an AECOPD for whom proactive
palliative care might be beneficial. We hypothesize that
the presence of two or more of the following indicators
(or prognostic conditions) should be a reason to start
proactive palliative care: 1) hypoxaemia or hypercapnia
at discharge; 2) treatment of the exacerbation with Non
Invasive Ventilation (NIV); 3) patient needs professional
home care service for personal care after discharge; 4) a
negative answer to the surprise question: ‘Would I (as
lung specialist) be surprised if this patient would have a
subsequent readmission for AECOPD within 8 weeks
and/or would die in the next year?; 5) the diagnosis of a
severe comorbidity such as: a) non-curable malignity or
b) cor pulmonale (proven or non proven) or c) proven
Chronic Heart Failure (CHF) or d) diabetes mellitus
with neuropathy or e) renal failure, clearance < 40 Glom-
erular Filtration Rate (GFR); 6) Clinical COPD Question-
naire (CCQ) total, day version ≥ 3; 7) Medical Research
Council dyspnea questionnaire (MRC dyspnea) = 5; 8)
Forced Expiratory Volume in 1 second (FEV1), measured
before AECOPD < 30% of predicted; 9) Body Mass Index
(BMI) < 21 or unplanned weight loss (> 10% weight loss in
last 6 months or > 5% in last month); 10) previous hospital
admissions for AECOPD (last 2 years ≥ 2 and/or last
year ≥ 1); 11) Age > 70 years.
In this study the discriminating power of this set of
indicators will be examined. We hypothesize that the set
of indicators can predict readmission within 8 weeks
and/or death within 1 year for patients hospitalized for
an AECOPD.
Organization of proactive palliative care for patients
with COPD
Provision of palliative care for patients with COPD in
Europe is variable, and overall very small [11]. The
majority of hospitals in Europe do not have a formalized
approach to palliative care issues for patients with
chronic lung disease. Besides patients with advanced
non-malignant respiratory disease have less universal ac-
cess to specialist palliative care services than those with
malignant lung disease [9-11]. In a survey performed in
the UK, the minority of hospital units had a formal re-
ferral pathway for palliative care and only about 13%
had a policy of initiating end-of-life discussions with
appropriate patients [30]. Although variation in care
may be influenced by many factors including availability,
access and reimbursement issues, such geographic varia-
tions suggest a lack of consensus concerning the best
approach to palliative care for patients with COPD [19].
Therefore, recent studies have focused on the best
approach and content of palliative care for patients with
COPD. It is suggested to start palliative care early beside
curative care [31]. Furthermore, good proactive palliative
care should at least consist of: 1) a standardized inven-
tory of current and future care needs and a structured
organization of proactive palliative care; 2) advance care
planning (ACP), which involves the patient (−family)-
clinician communication about end-of-life care and the
completion of advanced directives [20]. Important com-
ponents of ACP are discussions about the expected
course of the disease and prognosis and counseling con-
cerning preferences for care at the end of life, including
spiritual care [19]; 3) development and implementation
of a patient-tailored proactive palliative care plan. There
are several problems from the patient as well as from
the clinician perspective when it comes to satisfactory
implementation of ACP and a patient-tailored proactive
palliative care plan [7]. First, there are clinician and
patient related barriers to discuss ACP [32]. Patients for
instance avoid ACP discussions out of fear of suboptimal
treatment in case of emergencies while clinicians are
concerned that early ACP will take away patients’ hope
[20]. Discussions about ACP are therefore unlikely to
occur and when they do occur they are likely to be of
poor quality [19]. Second, not all clinicians have a
special interest in or are qualified to perform proactive
palliative care. Finally, delivering proactive palliative
care beside curative care for patients with COPD may
increase the workload and clinicians may be faced with
shortage of time [7]. In order to overcome these prob-
lems it is suggested that a multidisciplinary approach to
proactive palliative care with better access to specialist
palliative care services will help patients with COPD
navigate through the continuum of chronic disease
management and will improve quality of end-of-life
care [7,10].
Unfortunately, no research data is available on the
beneficial effects of a multidisciplinary approach to pro-
active palliative care for patients with COPD in terms of
reducing the healthcare utilization (for example, hospital
readmission) or improving quality of life. However, in a
study in male patients predominantly diagnosed with
cancer but also with cardiovascular and pulmonary dis-
eases, the benefits of palliative care provision appeared
effective compared with usual care [33]. Patients receiv-
ing palliative care were less likely to be admitted to the
ICU during hospitalization, had lower inpatient cost per
day and received better medical care provision compared
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to usual care patients. Hence proactive palliative care
may avoid admission to the ICU for patients with COPD
and may help to reduce health care costs. More research
data is available concerning the beneficial effects of an
early introduction of palliative care for patients with
cancer. In a recent study [34] the effect of introducing
early palliative care among patients diagnosed with
metastatic non-small-cell lung cancer was examined in a
randomized controlled trial (RCT). As compared to pa-
tients receiving standard care, patients receiving early
palliative care had a better quality of life, less depressive
symptoms, less aggressive care at the end of life and
longer survival.
In the present study the effects of proactive palliative
care performed by a specialized palliative care team for
patients with COPD on the wellbeing of these patients
and their informal caregivers will be examined. We
hypothesize that proactive palliative care for patients
with COPD will: increase the quality of life of these pa-
tients, decrease the number and length of acute hospital
admissions and ICU admissions, prolong survival of
these patients, decrease the number of patients that die
in the ICU, and decrease the level of overburdening of
their informal caregivers.
Methods/Design
Objectives
The PROLONG study exists of two parts, an indicator
study and an intervention study, each with its own
primary and secondary objectives:
Objectives indicator study
1. The primary objective is to assess the discriminating
power of a set of indicators that indicates the start
of proactive palliative care for patients with COPD.
2. The secondary objective is to examine to what
extend individual indicators (or clusters) indicative
are for the need of proactive palliative care.
Objectives intervention study
1. The primary objective is to assess the effects of
proactive palliative care delivered by a specialized
palliative care team on the wellbeing of patients
with COPD with poor prognosis and their informal
caregivers.
2. The secondary objective: is to assess survival rate in
COPD patients with proactive palliative care integrated
with standard care versus standard care only.
Study design
The study consists of a controlled trial (assessment)
with hospital as cluster, with a pre- and a post-test
assessment. In total 6 hospitals will participate, 3 hospi-
tals in the intervention condition and 3 hospitals in the
control condition. Hospitals are selected for the inter-
vention condition based on the presence of a specialized
palliative care team. In the hospitals in the control
condition standard care (usual care) will be delivered to
patients with COPD by their treating lung specialists. In
the hospitals in the intervention condition all patients
with COPD will receive standard care by their treating
lung specialist and those patients that are indicated for
proactive palliative care by our set of indicators will also
be supported by a specialized palliative care team on a
regular base. Baseline measurements of the intervention
study will be assessed from all participating patients dur-
ing hospitalization for AECOPD before start of the inter-
vention. Follow-up measurements will take place every
three months, starting from the moment of discharge
for a period of one year or until death. The primary out-
come measure of the indicator study is time to death for
any cause. The primary outcome measure of the inter-
vention study is the change in quality of life measured
by the St George Respiratory Questionnaire (SGRQ) at
three month after baseline. As pre-test assessment, data
will be obtained from the databases of the participating
hospitals over a one year period preceding the assess-
ment. These data on hospital-level are necessary to be
able to compare hospitals at baseline. As post-test as-
sessment, retrospectively the medical files of all partici-
pating patients will be examined over the assessment
period. The assessment will take 18 month; 6 month for
inclusion and 12 months for follow-up. The post-test
assessment will be performed in the 3 months after the
assessment.
Study population
Patients with a hospital admission for AECOPD will be
invited to participate. If they agree to participate, their
main informal caregiver will also be asked to participate.
Inclusion criteria
In order to be eligible to participate, a patient must meet
the following criteria:
 Being admitted to the hospital for AECOPD, and
 Aged 18 years or older.
Exclusion criteria
A patient that meets any of the following criteria will be
excluded from participation:
 Not speaking the Dutch language, or
 Having severe cognitive disorders, or
 At moment of inclusion being treated by a
specialized palliative care team.
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Intervention
In the hospitals in the intervention condition, members of
the specialized palliative care teams will receive a special
training in the provision of proactive palliative care for
patients with COPD. The training will be provided by
academic palliative care professionals of the Radboudumc
in Nijmegen. These trainings consist of two consecutive
meetings of three hours each. The first meeting will take
place in the month before start of the assessment. The
second meeting will take place in the first month of the
assessment. The following topics will be discussed:
 How to communicate end of life aspects with
patient and family;
 How to create a patient-tailored proactive palliative
care plan;
 How to anticipate on illness- and dying scenarios
proactively;
 How to organize transfer of care to lung specialist
and general practitioner (GP);
 How to perform a proactive palliative care plan in
cooperation with the lung specialist.
During the controlled trial patients in the intervention
condition who are assigned for proactive palliative care
will meet with a member of the specialized palliative
care team within one week after enrollment and at least
monthly thereafter in the outpatients setting for at least
one year or until death. The main informal caregiver of
the patient will be asked to be present at those meetings.
Guidelines for the proactive palliative care meetings in
the ambulatory setting are adapted from the general
guidelines palliative care in the Netherlands [35].
Study parameters
Outcome measures indicator study
1. Primary outcome measures:
a. Length of time from the moment that a patient
hospitalized for AECOPD meets two or more
criteria of the set of indicators to death for any cause.
2. Secondary outcome measures:
a. Length of time from the moment that a patient
hospitalized for AECOPD meets two or more
criteria of the set of indicators to the first
unexpected readmission to the hospital for
AECOPD.
b. The sensitivity and specificity of the set of
indicators, that indicate the start of proactive
palliative care for patients hospitalized for COPD,
in predicting death for any cause within 1 year.
c. The sensitivity and specificity of the set of
indicators, that indicate the start of proactive
palliative care for patients with COPD, in
predicting the first unexpected readmission to
hospital for AECOPD within 8 weeks.
d. Length of time from the moment that a patient
hospitalized for AECOPD meets two or more
criteria of the set of indicators to death as a result
of pulmonary insufficiency.
e. The sensitivity and specificity of the set of
indicators, that indicate the start of proactive
palliative care for patients hospitalized for COPD,
in predicting death as a result of pulmonary
insufficiency within 1 year.
f. The contribution of individual indicators (or
clusters), in predicting death for any cause within
1 year.
g. The contribution of individual indicators (or
clusters), in predicting the first unexpected
readmission to hospital for AECOPD within
8 weeks.
h. The contribution of individual indicators (or
clusters), in predicting death as a result of
pulmonary insufficiency within 1 year.
Outcome measures intervention study
1. The primary outcome measure is:
a. Change in quality of life (St George Respiratory
Questionnaire (SGRQ) [36]) of the patient
3 months after inclusion
2. The secondary outcome measures are:
Patient-related
a. Change in quality of life (SGRQ) of the patient 6,
9 and 12 months after inclusion
b. Change in quality of life at the end of life (McGill
Quality of Life questionnaire (McGill QOL) [37])
3, 6, 9 and 12 months after inclusion
c. Change in psychological wellbeing (Hospital
Anxiety and Depression Scale (HADS) [38]) 3, 6,
9 and 12 months after inclusion
d. Change in illness understanding 3, 6, 9 and
12 months after inclusion
e. Number and length of unexpected hospital
admissions
f. Number and length of unexpected ICU
admissions
g. Are the choices of Advance Care Planning (ACP)
documented in the medical file? (when yes/when no)
h. Place of death (ICU/hospital/hospice/nursing
home/at home)
i. Is preferred place of death known? (when yes/
when no)
j. Has this wish come true? (when yes/when no)
k. Length of survival of COPD patients with
proactive palliative care integrated with standard
care versus standard care only
Duenk et al. BMC Pulmonary Medicine 2014, 14:54 Page 5 of 13
http://www.biomedcentral.com/1471-2466/14/54
Informal caregiver-related
a. Change in informal caregiver burden (Self-Perceived
Pressure from Informal Care questionnaire (SPPIC)
[39]) 3, 6, 9 and 12 months after inclusion
b. Change in psychological wellbeing (HADS) at 3,
6, 9 and 12 months after inclusion
c. Change in illness understanding at 3, 6, 9 and
12 months after inclusion
Other study parameters
In order to take account of possible confounding vari-
ables, other parameters are: age, gender, marital status,
socio-economic status, smoking history, condition of liv-
ing (single, or living together), and place of living (home,
residential home, or nursing home).
Randomization
Randomization will not take place. Hospitals will be se-
lected for the intervention condition based on the pres-
ence of a specialized palliative care team in the hospital.
In order to be able to compare the hospitals in the
control- and the intervention condition a pre-test assess-
ment will be performed.
Study procedure
A description of the procedure is given to assess the
defined study parameters.
Pre-test assessment
The following data on hospital level will be obtain-
ed from the databases of the participating hospitals
retrospectively over a period of one year (1-1-2013 till
1-1-2014):
 Number of hospitalizations for AECOPD (including
ICU admissions)
 Number of unique patients hospitalized for
AECOPD (including ICU admissions)
 Total number of days of hospitalization of patients
with an AECOPD (including ICU admissions)
 Number of hospitalizations in the ICU (exclusively)
for AECOPD
 Number of unique patients hospitalized for
AECOPD in the ICU (exclusively)
 Total number of days of hospitalization of patients
with an AECOPD in the ICU (exclusively)
 Total number of patients hospitalized for AECOPD
that have died in the hospital (in the ICU or on the
nursing unit)
Training
Before start of the controlled trial (see Figure 2), mem-
bers of the specialized palliative care teams in the hospi-
tals in the intervention condition will receive a special
training in provision of proactive palliative care for
patients with COPD.
Controlled trial (assessment)
Patient Patients in the control condition will receive
standard care (usual care) only. Patients in the inter-
vention condition will receive standard care and, only
if they meet two or more criteria of the set of indica-
tors for proactive palliative care they will receive pro-
active palliative care integrated with standard care.
The procedure in the control condition will be first
described before describing the procedure in the inter-
vention condition.
In the hospitals in the control condition eligible
patients will be recruited the second day after hospital
admission. The treating lung specialist will give each
eligible patient oral and written information about the
study. The written information consists of an informa-
tion leaflet and two informed consent forms: one for
the patient and one for the informal caregiver. In the
information leaflet a description of the study, including
the nature of participation and phone numbers for
study contacts, are given for the patient and the infor-
mal caregiver. The lung specialist will obtain written
informed consent from the patient prior to enrollment.
If a patient has consented, a lung nurse will distribute
questionnaires for completion on the sixth day of hos-
pital stay or in case the patient is discharged earlier on
the day before leaving the clinic. After hospital dis-
charge the patient will be asked by the study coordin-
ator to complete questionnaires every 3 month until
the end of the study or until death. The questionnaires
will be sent to the patient by mail. A stamped retour
envelope will be enclosed.
In the hospitals in the intervention condition the same
procedure will be followed as in the hospitals in the con-
trol condition. In addition lung specialists will check if a
patient meets two or more criteria of the set of indica-
tors for proactive palliative care on the sixth day of
hospital admission or in case the patient is discharged
earlier on the day before leaving the clinic. If so, the lung
specialist will inform the specialized palliative care team.
Patients who are assigned for proactive palliative care
will preferably meet for the first time with a physician of
the specialized palliative care team before being dis-
missed from the hospital. If this is not possible the first
meeting will take place within 1 week after enrolment.
Thereafter, the specialized palliative care team will meet
with the patient monthly in the outpatients setting for at
least 1 year or until death.
Informal caregiver During hospital stay, each eligible
patient will identify a main informal caregiver, a relative
or friend whom he or she relies upon most for help. By
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sharing the written information with the informal care-
giver, the patient will provide the informal caregiver
with information about the study. The informal care-
giver can only participate if the patient is also partici-
pating. Once the informal caregiver has consented
questionnaires will be distributed during hospital stay
and every 3 month after hospital discharge of the
patient. These questionnaires will be sent in the same
envelop as the patient questionnaires.
Lung specialist The treating lung specialist will provide
standard care (usual care) to the patients hospitalized
R
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ea
r c
he
r
Informal caregiver: fills out
Baseline questionnaire
Demografic questionnaire
Hospitals intervention condition N=3
Inclusion: Patient hospitalized with an
AECOPD
Hospitals control condition N=3
Inclusion: Patient hospitalized with an
AECOPD
Patient: fills out before discharge hospital
Indicator questionnaires
Baseline questionnaires
Demografic questionnaire
Patient: fills out before discharge hospital
Indicator questionnaires
Baseline questionnaires
Demografic questionnaire
Informal caregiver: fills out
Baseline questionnaire
Demografic questionnaire
Proactive Palliative
care integrated
with Standard care
Standard care Standard care
Patient: fills out questionnaires:
SGRQ
McGill QOL
HADS
Illness understanding
Post-test assessment (retrospective medical file study) in the hospitals in the intervention- and the control condition
after completion of assessment
Informal caregiver: fills out questionnaires:
EDIZ
HADS
Illness understanding
Intervention based on
set of indicators for
proactive palliative care
Intervention:
The specialized
palliative care team
will meet with patient
on a regular base
Lu
ng
sp
ec
ia
lis
t
Lu
ng
sp
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li s
t
Follow up: every 3 month for 1 year
Choice hospitals for intervention- or control condition based on respectively
the presence or absence of a specialized palliative care team in a hospital
Figure 2 Study schema of the controlled trial (assessment) and the post-test assessment for PROLONG.
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for an AECOPD. After the patient has filled out and
returned the questionnaires the lung specialist in the
control- and the intervention condition will fill out a
case report form (CRF). The CRF consists of questions
about the measurement results of each indicator of the
set of indicators. The set of indicators is represented in
Table 1. Only in the intervention condition the lung spe-
cialist will check if a patient meets two or more criteria
of the set of indicators for proactive palliative care.
Specialized palliative care team The specialized pallia-
tive care teams in the hospitals in the intervention condition
consist of specially trained teams of professionals who pro-
vide care and support in inpatient and outpatient settings.
A team consists of at least a physician who is specialized in
palliative care, a nurse who is specialized in palliative care,
and preferably a psychologist and a spiritual counselor.
Post-test assessment
A post-test assessment will be performed in all partici-
pating hospitals. The medical files of all participating
patients will be examined retrospectively regarding the
assessment period on the following measures:
 Number and length of hospitalization of unexpected
hospital admissions for AECOPD
 Number and length of hospitalization of unexpected
ICU admissions for AECOPD
 Are the choices of Advance Care Planning (ACP)
documented in the medical file? (when yes/when
no)
 Place of death (ICU/hospital/hospice/nursing/home/
at home)
 Is preferred place of death known? (when yes/when
no)
 Has this wish come true? (when yes/when no)
 Length of survival after meeting conditions for
proactive palliative care
 The primary and secondary measures of the
indicator study
In order to take account of possible confounding vari-
ables, other parameters are: age, gender, marital status,
type of admission, (acute or planned), condition of living
(single, or living together), place of living (home, resi-
dential home, or nursing home), Gold stage, comorbidi-
ties, and date of diagnosis.
Tools to help the clinical decision making
In order to help the clinical decision making, the
specialized palliative care team will make use of two
additional tools: 1) the Problems and Needs in Palliative
Care questionnaire short version (PNPC-sv) and 2) the
Proactive Palliative Care Planning Card (PPCPC).
The PNPC-sv patient is a concise, patient-centered
tool that helps to identify the problems affecting the pa-
tient’s quality of life and (unmet) needs for care. This
self-report questionnaire is covering all dimensions of
palliative care. The questionnaire consists of 36 items
and is a reliable and valid tool [40].
The PPCPC is a tool that can be used by members of
the specialized palliative care team to structure the dis-
cussion with the patient and his/her informal caregiver.
This tool is especially useful when exploring the actual
en potential problems and needs of the patient [41].
Data collection
Data collection will take place by administration of ques-
tionnaires to the participating patients and their informal
caregivers and by retrospectively collecting data from the
medical files of the participating patients over the assess-
ment period. The type of questionnaires for patients and in-
formal caregivers, the frequency of their administration and
the retrospectively collected data are detailed in Table 2.
Instrument selection
Questionnaires used as indicator
In order to be able to decide whether or not to start pro-
active palliative care, questionnaires used as indicator will
be filled out by the patient.
Table 1 Set of indicators for proactive palliative care
A patient hospitalized for AECOPD is eligible for proactive
palliative care when meeting two or more criteria of the following
set of indicators:
1. Hypoxaemia or hypercapnia at discharge
2. Treatment of the exacerbation with Non Invasive Ventilation (NIV)
3. Patient needs professional home care service for personal care after
discharge
4. Negative answer to the surprise question: ‘Would I (as lung
specialist) be surprised if this patient would have a subsequent
readmission for AECOPD within 8 weeks and/or would die in the
next year?
5. The diagnosis of a severe comorbidity such as:
a. Non-curable malignity or
b. Cor pulmonale (proven or non proven) or
c. Proven Chronic Heart Failure (CHF) or
d. Diabetes mellitus with neuropathy or
e. Renal failure, clearance < 40 (GFR: in ml/min)
6. CCQ total, day version ≥ 3
7. MRC dyspnea = 5
8. FEV1 (measured before AECOPD) < 30% of predicted
9. BMI < 21 or unplanned weight loss (> 10% weight loss in last 6
months or > 5% in last month)
10. Previous hospital admissions for AECOPD (last 2 years ≥ 2 and/or
last year ≥ 1)
11. Age > 70 years
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We will use the CCQ day version to measure health
status of patients. The CCQ is a questionnaire for self-
administration specially developed to measure health
status in patients with COPD and is valid, responsive,
and reliable [42,43]. The CCQ consists of 10 questions
rated on a seven point Likert scale. Higher scores repre-
sent a worse health status. Questions are divided into
three domains: symptoms (4 questions), functional status
(4 questions), and mental state (2 questions).
The MRC dyspnea scale has been in use for many
years for grading the effect of breathlessness on daily
activities [44]. The MRC dyspnea scale consists of 5
questions and provides a simple and valid method of
categorizing patients in terms of their disability due to
COPD [44]. The patient’s dyspnea is rated from 1–5 in
terms of severity, with the higher the grade, the more
severe the dyspnea. During the study MRC dyspnea will
be measured by asking about the circumstances two
weeks before hospital admission.
Questionnaires used as outcome measures
Patient questionnaires The SGRQ is a specific quality
of life questionnaire for obstructive respiratory diseases
[36]. It consists of 50 questions from which a total score
is calculated. It is divided into three subscales: symptoms
(8 items related to patients’ recollection of their symp-
toms), activities (16 items on physical activities which
are caused or limited by dyspnea), and impacts (26 items
on the social and physiologic effects of the disease). The
final score obtained ranges from zero to 100. A higher
score indicates a lower quality of life. A score change of
4 points or more is considered significant in the quality
of life of the patient [45]. The SGRQ is a reliable and
valid measure of the quality of life in patients with
COPD [46].
The McGill QOL is designed to assess quality of life in
patients with a life-threatening illness [37]. The question-
naire consists of 16 items with an 11-point scale (0–10)
with appropriate anchors. It includes 5 domains: physical
symptoms, physical well-being, psychological well-being,
existential issues and support. The mean of all 5 domains
is presented as McGill QOL total score. The acceptability,
internal consistency, reliability and validity of the McGill
QOL have been assessed in patients receiving palliative
care [47].
The HADS will be used to assess psychological well-
being in patients. The HADS is a self-assessment 14-item
questionnaire. It has two 7-item subscales assessing de-
pression and anxiety in the preceding week. The format
consists of four answering categories (0–3) that quantify
the degree to which a particular emotion is experienced
by the patient. The score on each subscale ranges from 0
to 21 and a score larger than 11 is considered to be con-
sistent with definitive depression and anxiety. A score less
Table 2 Overview of outcome measures per time point in
the PROLONG study
Outcome measures B 3 m 6 m 9 m 12 m R
Questionnaires
Patient
CCQ X
MRC dyspnea X
SGRQ X X X X X
McGill QOL X X X X X
HADS X X X X X
Illness understanding X X X X X
Demographic questionnaire X
Informal caregiver
SPPIC X X X X X
HADS X X X X X
Illness understanding X X X X X
Demographic questionnaire X
Lung specialist
CRF X
Medical files
Number of hospitalisations of
unexpected hospital admissions
for AECOPD
X
Number of days of unexpected
hospital admissions for AECOPD
X
Number of hospitalisations of
unexpected ICU admissions for AECOPD
X
Number of days of unexpected ICU
admissions for AECOPD
X
Are the choices of ACP documented in
the medical file at baseline? (when
yes/when no)
X
Are the choices of ACP documented in
the medical file after one year or at time
of death? (when yes/when no)
X
Did the patient die within one year after
inclusion? (when yes/when no)
X
Date of death X
Place of death (ICU/hospital/hospice/
nursing home/at home)
X
Is preferred place of death known?
(when yes/when no)
X
Has this wish come true? (when yes/
when no)
X
Primary cause of death (pulmonary
insufficiency/other cause)
X
Secondary cause of death (pulmonary
insufficiency/other cause)
X
Did the patient have an unexpected
hospital readmission for AECOPD within
8 weeks? (when yes/when no)
X
Date of first unexpected hospital
readmission for AECOPD.
X
B = baseline; m =month; R = retrospectively.
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than 7 is normal and a score of 8–10 is considered border-
line for depression and anxiety [38].
Patients with COPD tend to be poorly informed about
the long-term prognosis of COPD and what to expect to-
ward the end of life [48]. They may not realize that COPD
is incurable and fatal. They also may not always attribute
repeated exacerbations to advancing disease but instead
seeing them as temporary setbacks caused by activities,
environmental factors, faltering self-management, or in-
fection. Toward the end of life this lack of understanding
may impair quality of life [2,49]. There are no validated
tools to assess illness understanding in patients with
COPD. Therefore, we adapted an illness understanding
questionnaire used in studies of patients with advanced
cancer [50]. The questionnaire consists of 4 self-report
items which can be answered by yes or no.
Patients will be asked in a demographic questionnaire
to indicate their sex, age, marital status, education,
smoking history, living situation, name of main informal
caregiver and kind of relationship with their main infor-
mal caregiver.
Informal caregiver questionnaires The Self-Perceived
Pressure from Informal Care questionnaire (SPPIC) is a
non-disease specific instrument assessing the demands
of the informal caregiver situation [39]. This instrument
consists of nine statements that form a hierarchical scale
that varies from less to more pressure. The statements
are all related to the subjective perception of the infor-
mal caregiver. It is a validated and easy to use instru-
ment since completing it takes less than 5 minutes.
The HADS (see patient questionnaires) will also be
used in informal caregivers to assess psychological well-
being. An adapted version of the illness understanding
questionnaire for patients will be used for the informal
caregivers as well. Finally, informal caregivers will be
asked to indicate their sex, age and education in a demo-
graphic questionnaire.
Sample size calculation
The primary outcome in the intervention study is the
quality of life of the patients measured with the SGRQ.
More specifically the change in SGRQ three month after
inclusion is the variable of interest. Koff et al. [51] pub-
lished a difference in change of 9 between the two
groups (standard care, standard care with proactive pal-
liative care) with a common standard deviation of
the change of 16. Then 64 patients would be needed in
each group to obtain a power of 80% (two-sided t-test,
alpha = 0.05). To adjust for the clustering at hospital
level (ICC = 0.01, three hospitals per arm) and to allow
for an additional loss to follow up of 10% a total of 86
patients are needed in each arm. This means that in
each hospital 29 patients with an AECOPD are needed
who have a poor prognosis according to our criteria.
We expect to have to include between 60 and 90 pa-
tients with an AECOPD in each hospital to get suffi-
cient patients that meet at least 2 criteria of the set of
indicators.
Statistical analysis
Study parameter(s) indicator study
Non-continuous data will be reported as frequencies.
Continuous variables normally distributed will be re-
ported as mean ± standard deviation (SD). Not normally
distributed data will be reported as median (interquartile
range, IQR). The analytical plan consists of two steps.
The first step will be to explore the discriminating power
of meeting two or more criteria of the set of indicators
for predicting death within one year and predicting un-
expected hospital admission, respectively. The sensitivity
and specificity for both death within one year and for
unexpected admission to hospital will be presented. The
second step will be to explore the discriminating power
of individual indicators (or clusters) in predicting death
within one year or unexpected admission to hospital.
Univariable and multivariable logistic regression will be
performed to examine which variables or cluster of vari-
ables are associated with death within one year (unex-
pected admission to hospital respectively). Variables will
be eliminated one by one from the model based on like-
lihood ratio tests. Variables are eligible for inclusion into
the final model if they are significantly associated with
death within one year (unexpected admission to hospital
respectively), with a p-value of < 0.10.
Study parameter(s) intervention study
Frequencies, means and standard deviations will be used
to describe the study variables. Differences between the
study groups in baseline characteristics and clinical
outcomes will be assessed and tested for statistical
significance with the use of two-sided Fisher’s exact
tests and chi-square tests for categorical variables and
independent-samples t-tests for continuous variables.
The primary study outcome measure of the interven-
tion study is the change in the score on the SGRQ from
baseline to 3 months: a paired t-test will be used to test
the difference between the groups for statistical signifi-
cance. Linear mixed models, with adjustment for base-
line scores, will be used to study the effect of proactive
palliative care on SGRQ outcomes during the follow-up
period. The analysis follows the principle of intention
to treat. Survival time will be calculated from the date
of enrollment to the date of death with the use of the
Kaplan-Meier method. A Cox proportional-hazard model
will be used to assess the effect of proactive palliative
care on survival, with adjustment for demographic
characteristics.
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Ethical considerations
Patients with COPD who participate in the study may be
vulnerable but are certainly capacitated adults. Since this
is a therapeutic research the participants, patients and
informal caregivers, may even benefit from participation.
The potential risks of this study are quite small. They
relate to the burden of filling in questionnaires. This will
take the patient about 20–30 minutes every three
months. The potential benefits on the other hand are
comparatively large. First, participating patients with
severe COPD and their informal caregivers in the inter-
vention condition will get, if indicated for it, extra
proactive palliative care. Second, this study may lead to
better understanding of the conditions to start and the
effectiveness of proactive palliative care for patients with
COPD. Third, there is a potentially benefit for society
since results of this study may ultimately lead to differ-
ent and improved clinical approaches to care of patients
with severe COPD.
This Study has been approved by the Medical Ethics
Committee (CMO) of the Radboud University Nijmegen
Medical Centre (METC protocol number 2012/260).
Discussion
Research on the effectiveness of palliative care for the
COPD patient is scarce and inconclusive [52]. The
PROLONG study is the first prospective controlled trial
evaluating the effectiveness of a multidisciplinary ap-
proach to palliative care in COPD disease. The outcomes
of this study will give insight in the discriminating
power of a set of indicators for proactive palliative care
and the effectiveness of proactive palliative care for
patients with COPD.
In the Netherlands, COPD is on the sixth place of
causes of death for people older than 45 years. In 2011
6,535 patients died with COPD as primary cause of death
while in 2010 the number of hospitalizations of patients
with COPD as diagnosis was 22,5440. The prevalence of
COPD in the Netherlands is high (361,800 in 2011) and
will, with the aging of the population, further increase the
coming years [53]. Up to now patients with COPD hardly
receive palliative care. The above mentioned numbers re-
veal the social relevance of introducing palliative care for
patients with COPD. Furthermore, introducing palliative
care for patients with COPD can possibly be cost-saving
since palliative care may lead to reduction of acute care
[33,54,55].
We have chosen a cluster controlled design for the PRO-
LONG study to prevent cross-contamination of the inter-
vention within a hospital. At the moment of recruitment of
hospitals the minority of hospitals in the Netherlands had
the availability of a specialized palliative care team. There-
fore, it was not an option to perform a randomized cluster
controlled trial. Hospitals are selected for the intervention
condition based on the presence of a specialized palliative
care team in the hospital. In order to be able to compare
the hospitals in the control- and the intervention condition
at baseline a pre-test assessment will be performed.
Recruitment for trials of patients with poor prognosis
is often difficult. In order to ensure a sufficiently large
sample for the PROLONG study broad inclusion criteria
will be used. All patients hospitalized with an AECOPD
over 17 years old can be screened for the study. This will
facilitate lung specialists to include patients. Only after
inclusion the distinction between patients with poor or
better prognosis will be made in order to decide who is
eligible for the intervention condition.
The PROLONG study may lead to better understand-
ing of the conditions to start and the effectiveness of
proactive palliative care for patients with COPD. The
innovative aspects of the PROLONG study are: 1) the
use of a set of indicators to identify patients hospitalized
with an AECOPD who are in need of proactive palliative
care, 2) the active involvement of a specialized palliative
care team in the development and the implementation
of proactive palliative care for patients with COPD and,
3) the use of a patient-tailored proactive palliative care
plan in which lung specialist and a specialized palliative
care team work together to optimize proactive palliative
care for the COPD patient. This patient-tailored pro-
active palliative care plan is intended to meet and to
adjust to the individual needs, wishes, possibilities and
limitations of the patient and the informal caregiver.
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